Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity

Infection and Immunity
Jo Anne Welsch, Dan Granoff

Abstract

The hallmark of immunity to meningococcal disease is a bactericidal titer in serum of > or =1:4 measured with human complement, but this threshold titer may underestimate the extent of protection. We used the infant rat model of meningococcal bacteremia to measure group C passive protective activity in serum samples from 91 unimmunized adults living in California. A total of 35 sera (38.5%) had passive protective activity. Sera with complement-mediated bactericidal titers of > or =1:4 were 3.4-fold more likely to confer protection (89%) than nonbactericidal sera (26%; P < 0.0001). Thus, bactericidal titers of > or =1:4 are a marker of protection, but this threshold lacks sensitivity for predicting protective activity. We investigated the 73 sera with bactericidal titers of <1:4 to determine the basis of protective activity. The 19 sera with protective activity had a higher geometric mean group C anticapsular antibody concentration (0.72 microg/ml) than the 54 sera that lacked protective activity (0.16 microg/ml; P < 0.001). Thus, protective activity in the absence of bactericidal activity was associated with higher concentrations of anticapsular antibodies, but not all sera with anticapsular antibodies conferred protection. Of ...Continue Reading

References

Nov 1, 1973·The Journal of Experimental Medicine·I W Devoe, J E Gilchrist
Jan 1, 1973·The Journal of Infectious Diseases·L B RellerH N Beaty
Jun 1, 1969·The Journal of Experimental Medicine·I GoldschneiderM S Artenstein
Jun 1, 1969·The Journal of Experimental Medicine·I GoldschneiderM S Artenstein
Mar 18, 2000·The Journal of Infectious Diseases·G R JonesJ E Heckels
Aug 31, 2000·Biologicals : Journal of the International Association of Biological Standardization·L JodarI M Feavers
Feb 13, 2001·Vaccine·A J Pollard, C Frasch
Apr 17, 2001·The Pediatric Infectious Disease Journal·A H Lucas, D M Granoff
May 1, 2001·Clinical and Diagnostic Laboratory Immunology·G F SantosD M Granoff
Jan 25, 2002·The Journal of Infectious Diseases·David GoldblattElizabeth Miller
Oct 3, 2002·Journal of Medical Microbiology·P BalmerE Miller
Jun 7, 2003·The Pediatric Infectious Disease Journal·Colin W ShepardUNKNOWN Active Bacterial Core Surveillance Team
Jul 19, 2003·Science·Linda JohanssonAnn-Beth Jonsson
Jan 30, 2004·Annual Review of Medicine·Pratima L RaghunathanNancy E Rosenstein
Apr 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jo Anne WelschDan M Granoff

❮ Previous
Next ❯

Citations

May 28, 2008·The Journal of Experimental Medicine·Maria Jose UriaChristoph M Tang
Jan 19, 2006·Clinical Microbiology Reviews·Lee H Harrison
Nov 23, 2011·Infection and Immunity·David M VuDan M Granoff
Mar 19, 2005·Pediatric Research·Clementien L VermontGermie P J M van den Dobbelsteen
Jan 9, 2013·Human Vaccines & Immunotherapeutics·Emanuelle B GasparElizabeth De Gaspari
Feb 22, 2005·Journal of Theoretical Biology·Vincent A A JansenDominik Wodarz
Oct 20, 2017·Human Vaccines & Immunotherapeutics·Helen Petousis-Harris
Sep 23, 2006·Expert Review of Vaccines·Harry L KeyserlingGregory P Gilmet
Mar 13, 2009·Clinical and Vaccine Immunology : CVI·Rachel A FosterAndrew W Heath
Feb 18, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Peter T BeerninkDan M Granoff
Dec 20, 2019·Therapeutic Advances in Vaccines and Immunotherapy·Gabriela Trzewikoswki de LimaElizabeth De Gaspari
Jan 26, 2010·Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.